Sanofi named Dr. David Meeker CEO of Genzyme Corp., the Cambridge, Mass.-based biotechnology company that Sanofi acquired earlier this year.
Sanofi promotes Meeker to Genzyme CEO
Meeker, 57, has served as Genzyme's COO since 2009 and is a former director of the pulmonary critical-care fellowship at the Cleveland Clinic, according to a Sanofi news release. In his new position, Meeker will report to Christopher Viehbacher, CEO of Sanofi and chairman of Genzyme.
Genzyme's chairman and CEO, Henri Termeer, resigned at the time of the deal.
Paris-based Sanofi also said in the news release that Genzyme will incorporate the company's rare-disease business and the multiple sclerosis franchise. Genzyme’s company's renal, biosurgery and oncology divisions have already been integrated into Sanofi's portfolio.
Meeker's appointment is effective Nov. 1.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.